NPS Pharmaceuticals, Inc has announced that SmithKline Beecham (SB) will continue funding work at NPS under an existing collaborative research and license agreement begun in 1993. NPS and SB are engaged in research efforts to find novel therapies for osteoporosis. Under the terms of the agreement, SB has also purchased shares of NPS stock. The Read more about SmithKline Beecham To Extend Agreement With NPS Pharmaceuticals[…]